Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Choose the right SP 500 fund for retirement in 2024 by evaluating fees, track record, and diversification.
24,199 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
If SpaceX shifts a sizable slice of its IPO to everyday investors, the market could see bigger demand and new pricing...
AI-powered platforms are cutting construction draw timelines dramatically, compressing review cycles from days to hou...
AFC Gamma investors are watching the Q1 2026 earnings call closely. This guide breaks down what to expect, how to rea...
Rocket Lab rockets higher after a record Q1 FY2026 showing strong revenue and a bloated backlog, signaling momentum f...
Memory chips are fueling a renewed AI stock rally, but Harvard’s Willy Shih cautions that the boom could cool. Here’s...
The (feam) 2026 earnings call offers more than numbers. It reveals management’s strategy, how FEAM is navigating cost...
A fresh take on LUCD's early 2026 results, this analysis dives into the lucd 2026 earnings transcript to unpack reven...
A routine ethics filing has become a focal point for investors and policymakers. This deep dive explains what the qua...
Investors eyeing SPRY's Q1 2026 results should understand how to parse a pharma earnings transcript. This guide break...
Ecopetrol sits at the crossroads of a volatile energy market and a growing emerging markets economy. This deep dive b...
A Philadelphia primary delivers a surprise win for a self-described 'proud troublemaker' democratic socialist, beatin...